<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:50:23 -0700</creation_date>
  <update_date>2013-05-27 11:40:00 -0600</update_date>
  <accession>HMDBP00484</accession>
  <secondary_accessions>
    <accession>5726</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>UDP-glucuronosyltransferase 1-I</synonym>
    <synonym>UDP-glucuronosyltransferase 1A9</synonym>
    <synonym>UDPGT 1-9</synonym>
    <synonym>UGT-1I</synonym>
    <synonym>UGT1*9</synonym>
    <synonym>UGT1-09</synonym>
    <synonym>UGT1.9</synonym>
    <synonym>UGT1I</synonym>
    <synonym>lugP4</synonym>
  </synonyms>
  <gene_name>UGT1A9</gene_name>
  <general_function>Involved in transferase activity, transferring hexosyl groups</general_function>
  <specific_function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols.
</specific_function>
  <pathways>
    <pathway>
      <name>Pentose and glucuronate interconversions</name>
      <smpdb_id/>
      <kegg_map_id>map00040</kegg_map_id>
    </pathway>
    <pathway>
      <name>Ascorbate and aldarate metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00053</kegg_map_id>
    </pathway>
    <pathway>
      <name>Steroid hormone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00140</kegg_map_id>
    </pathway>
    <pathway>
      <name>Starch and sucrose metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00500</kegg_map_id>
    </pathway>
    <pathway>
      <name>Retinol metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00830</kegg_map_id>
    </pathway>
    <pathway>
      <name>Porphyrin and chlorophyll metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00860</kegg_map_id>
    </pathway>
    <pathway>
      <name>Metabolism of xenobiotics by cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00980</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00982</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - other enzymes</name>
      <smpdb_id/>
      <kegg_map_id>map00983</kegg_map_id>
    </pathway>
    <pathway>
      <name>Chemical carcinogenesis</name>
      <smpdb_id/>
      <kegg_map_id>map05204</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00901</accession>
      <name>Valproic acid glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01272</accession>
      <name>Nicotine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04482</accession>
      <name>2-Methoxyestrone 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04483</accession>
      <name>Estrone glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06224</accession>
      <name>17-beta-Estradiol-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10316</accession>
      <name>Acetaminophen glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10317</accession>
      <name>17-beta-Estradiol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10318</accession>
      <name>Pregnanediol-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10322</accession>
      <name>17-alpha-Estradiol-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10325</accession>
      <name>Ethyl glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10334</accession>
      <name>Ketoprofen glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10335</accession>
      <name>Estriol-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10340</accession>
      <name>Retinyl beta-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10343</accession>
      <name>1-(alpha-Methyl-4-(2-methylpropyl)benzeneacetate)-beta-D-Glucopyranuronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10352</accession>
      <name>3-alpha,20-alpha-Dihydroxy-5-beta-pregnane 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10354</accession>
      <name>16-alpha,17-beta-estriol 17-beta-D-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10356</accession>
      <name>Estriol 3-sulfate 16-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10364</accession>
      <name>11-Hydroxyprogesterone 11-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00010</accession>
      <name>2-Methoxyestrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00031</accession>
      <name>Androsterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00054</accession>
      <name>Bilirubin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00145</accession>
      <name>Estrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00153</accession>
      <name>Estriol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00295</accession>
      <name>Uridine 5'-diphosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00405</accession>
      <name>2-Methoxyestradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00490</accession>
      <name>Etiocholanolone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00496</accession>
      <name>3-Methoxy-4-hydroxyphenylglycol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00935</accession>
      <name>Uridine diphosphate glucuronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01013</accession>
      <name>Cotinine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01204</accession>
      <name>trans-3-Hydroxycotinine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01852</accession>
      <name>All-trans-retinoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02091</accession>
      <name>Isovalerylglucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02513</accession>
      <name>Lithocholate 3-O-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02577</accession>
      <name>Cholic acid glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02579</accession>
      <name>Glycochenodeoxycholic acid 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02596</accession>
      <name>Deoxycholic acid 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02829</accession>
      <name>Androsterone glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02833</accession>
      <name>Testosterone sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03141</accession>
      <name>Retinoyl b-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03193</accession>
      <name>Testosterone glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03325</accession>
      <name>Bilirubin diglucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04484</accession>
      <name>Etiocholanolone glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04995</accession>
      <name>Codeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06203</accession>
      <name>5-alpha-Dihydrotestosterone glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06765</accession>
      <name>2-Methoxy-estradiol-17b 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06766</accession>
      <name>Estriol-16-Glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10313</accession>
      <name>1-Salicylate glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10315</accession>
      <name>4-Hydroxyandrostenedione glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10319</accession>
      <name>Inodxyl glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10320</accession>
      <name>Cortolone-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10321</accession>
      <name>3,17-Androstanediol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10323</accession>
      <name>Phenethylamine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10324</accession>
      <name>Benzoyl glucuronide (Benzoic acid)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10326</accession>
      <name>Thyroxine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10327</accession>
      <name>Dehydroisoandrosterone 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10328</accession>
      <name>Tyramine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10329</accession>
      <name>Dopamine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10330</accession>
      <name>Cholesterol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10331</accession>
      <name>Palmitoyl glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10332</accession>
      <name>Bilirubin glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10333</accession>
      <name>Estriol-17-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10336</accession>
      <name>Epinephrine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10337</accession>
      <name>6-Dehydrotestosterone glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10338</accession>
      <name>11-Oxo-androsterone glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10339</accession>
      <name>3-alpha-Androstanediol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10341</accession>
      <name>Dextrorphan O-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10342</accession>
      <name>25-Hydroxyvitamin D2-25-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10344</accession>
      <name>Vitamin D2 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10345</accession>
      <name>Aldosterone 18-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10346</accession>
      <name>Triiodothyronine glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10347</accession>
      <name>Octanoylglucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10348</accession>
      <name>Dehydroepiandrosterone 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10350</accession>
      <name>2-Phenylethanol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10351</accession>
      <name>11-beta-Hydroxyandrosterone-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10353</accession>
      <name>15-Hydroxynorandrostene-3,17-dione glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10355</accession>
      <name>Cholestane-3,7,12,25-tetrol-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10357</accession>
      <name>Tetrahydroaldosterone-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10359</accession>
      <name>17-Hydroxyandrostane-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10360</accession>
      <name>25-Hydroxyvitamin D2 25-(beta-glucuronide)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10361</accession>
      <name>(23S)-23,25-dihdroxy-24-oxovitamine D3 23-(beta-glucuronide)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10362</accession>
      <name>6-Hydroxy-5-methoxyindole glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10363</accession>
      <name>5-Hydroxy-6-methoxyindole glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10365</accession>
      <name>3-alpha-hydroxy-5-alpha-androstane-17-one 3-D-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01390</accession>
      <name>Hydroxycotinine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12226</accession>
      <name>Entacapone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13897</accession>
      <name>4-ene-Valproic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14542</accession>
      <name>Sorafenib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14645</accession>
      <name>Haloperidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14826</accession>
      <name>Mycophenolate mofetil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14850</accession>
      <name>Flurbiprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14869</accession>
      <name>Nateglinide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13968</accession>
      <name>Hydroxyzileuton</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14900</accession>
      <name>Irinotecan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14018</accession>
      <name>4-Hydroxypropofol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15159</accession>
      <name>Mycophenolic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15403</accession>
      <name>Lumiracoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15573</accession>
      <name>Niflumic Acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00127</accession>
      <name>D-Glucuronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00580</accession>
      <name>Chondroitin sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00639</accession>
      <name>Galactaric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00652</accession>
      <name>Chondroitin 4-sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00663</accession>
      <name>Glucaric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00693</accession>
      <name>Heparan sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01394</accession>
      <name>Heparin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02061</accession>
      <name>Hyaluronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02429</accession>
      <name>(3a,5b)-24-oxo-24-[(2-sulfoethyl)amino]cholan-3-yl-b-D-Glucopyranosiduronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02430</accession>
      <name>(3a,5b,7a)-23-Carboxy-7-hydroxy-24-norcholan-3-yl-b-D-Glucopyranosiduronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02472</accession>
      <name>(3a,5b,7a,12a)-24-[(carboxymethyl)amino]-1,12-dihydroxy-24-oxocholan-3-yl-b-D-Glucopyranosiduronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02545</accession>
      <name>Galacturonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02704</accession>
      <name>Iduronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03363</accession>
      <name>Pectic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03402</accession>
      <name>Pectin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03976</accession>
      <name>D-Glucuronic acid 1-phosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10349</accession>
      <name>Estradiol-17alpha 3-D-glucuronoside</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10358</accession>
      <name>17-beta-estradiol 3-sulfate-17-(beta-D-glucuronide)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10366</accession>
      <name>Hyaluronan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11658</accession>
      <name>2,8-Dihydroxyquinoline-beta-D-glucuronide </name>
    </metabolite>
    <metabolite>
      <accession>HMDB11686</accession>
      <name>p-Cresol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12302</accession>
      <name>UDP-D-galacturonate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12304</accession>
      <name>UDP-L-iduronate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13847</accession>
      <name>Losartan N2-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14551</accession>
      <name>Ardeparin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14709</accession>
      <name>Fondaparinux sodium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15356</accession>
      <name>Enoxaparin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29212</accession>
      <name>Quercetin 3-O-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29214</accession>
      <name>Quercetin-4'-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29357</accession>
      <name>Betavulgaroside I</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29406</accession>
      <name>Amaranthin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29500</accession>
      <name>Kaempferol 3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29844</accession>
      <name>Glyciram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29881</accession>
      <name>D-Glucaric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29917</accession>
      <name>2-O-(4-O-Methyl-a-D-glucopyranuronosyl)-D-xylose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29923</accession>
      <name>Xanthan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29938</accession>
      <name>Acaciabiuronic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB29940</accession>
      <name>Alginic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB30498</accession>
      <name>Camelliasaponin A1</name>
    </metabolite>
    <metabolite>
      <accession>HMDB30499</accession>
      <name>Camelliasaponin A2</name>
    </metabolite>
    <metabolite>
      <accession>HMDB30976</accession>
      <name>Durupcoside B</name>
    </metabolite>
    <metabolite>
      <accession>HMDB30977</accession>
      <name>Durupcoside A</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31022</accession>
      <name>Elatoside I</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31023</accession>
      <name>Achyranthoside D</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31024</accession>
      <name>Achyranthoside C</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31025</accession>
      <name>Betavulgaroside IV</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31026</accession>
      <name>Calenduloside H</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31027</accession>
      <name>Tuberoside B (Ullucus tuberosus)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31353</accession>
      <name>Kudzusaponin SA4</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31656</accession>
      <name>Jaceidin 4'-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31883</accession>
      <name>Sandosaponin B</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31884</accession>
      <name>Sandosaponin A</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31959</accession>
      <name>Lablaboside D</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31960</accession>
      <name>Lablaboside E</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31961</accession>
      <name>Lablaboside F</name>
    </metabolite>
    <metabolite>
      <accession>HMDB31965</accession>
      <name>Melilotussaponin O1</name>
    </metabolite>
    <metabolite>
      <accession>HMDB33105</accession>
      <name>N2-Galacturonyl-L-lysine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB33106</accession>
      <name>N6-Galacturonyl-L-lysine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB34379</accession>
      <name>Silenoside A</name>
    </metabolite>
    <metabolite>
      <accession>HMDB34389</accession>
      <name>Silenoside B</name>
    </metabolite>
    <metabolite>
      <accession>HMDB34390</accession>
      <name>Silenoside C</name>
    </metabolite>
    <metabolite>
      <accession>HMDB41796</accession>
      <name>2,2,2-Trichloroethanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB42049</accession>
      <name>Trichloroethanol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60510</accession>
      <name>SN-38</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60511</accession>
      <name>SN38 glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60464</accession>
      <name>Codeine-6-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14440</accession>
      <name>Morphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB41936</accession>
      <name>Morphine-3-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB41937</accession>
      <name>Morphine-6-glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB41809</accession>
      <name>4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60383</accession>
      <name>4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60498</accession>
      <name>NNAL-N-glucuronide</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring glycosyl groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring hexosyl groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>enzyme binding</description>
      <go_id>GO:0019899</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>enzyme inhibitor activity</description>
      <go_id>GO:0004857</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>glucuronosyltransferase activity</description>
      <go_id>GO:0015020</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>retinoic acid binding</description>
      <go_id>GO:0001972</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>drug metabolic process</description>
      <go_id>GO:0017144</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>flavone metabolic process</description>
      <go_id>GO:0051552</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>flavonoid glucuronidation</description>
      <go_id>GO:0052696</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of fatty acid metabolic process</description>
      <go_id>GO:0045922</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>retinoic acid metabolic process</description>
      <go_id>GO:0042573</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic glucuronidation</description>
      <go_id>GO:0052697</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Microsome</subcellular_location>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Single-pass membrane protein (Potential)</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>2</chromosome_location>
    <locus>2q37</locus>
    <gene_sequence>&gt;1593 bp
ATGGCTTGCACAGGGTGGACCAGCCCCCTTCCTCTATGTGTGTGTCTGCTGCTGACCTGT
GGCTTTGCCGAGGCAGGGAAGCTACTGGTAGTGCCCATGGATGGGAGCCACTGGTTCACC
ATGAGGTCGGTGGTGGAGAAACTCATTCTCAGGGGGCATGAGGTGGTTGTAGTCATGCCA
GAGGTGAGTTGGCAACTGGGAAGATCACTGAATTGCACAGTGAAGACTTATTCAACTTCA
TATACCCTGGAGGATCTGGACCGGGAGTTCAAGGCTTTTGCCCATGCTCAATGGAAAGCA
CAAGTACGAAGTATATATTCTCTATTAATGGGTTCATACAATGACATTTTTGACTTATTT
TTTTCAAATTGCAGGAGTTTGTTTAAAGACAAAAAATTAGTAGAATACTTAAAGGAGAGT
TCTTTTGATGCAGTGTTTCTCGATCCTTTTGATAACTGTGGCTTAATTGTTGCCAAATAT
TTCTCCCTCCCCTCCGTGGTCTTCGCCAGGGGAATACTTTGCCACTATCTTGAAGAAGGT
GCACAGTGCCCTGCTCCTCTTTCCTATGTCCCCAGAATTCTCTTAGGGTTCTCAGATGCC
ATGACTTTCAAGGAGAGAGTACGGAACCACATCATGCACTTGGAGGAACATTTATTATGC
CACCGTTTTTTCAAAAATGCCCTAGAAATAGCCTCTGAAATTCTCCAAACACCTGTTACG
GAGTATGATCTCTACAGCCACACATCAATTTGGTTGTTGCGAACGGACTTTGTTTTGGAC
TATCCCAAACCCGTGATGCCCAACATGATCTTCATTGGTGGTATCAACTGCCATCAGGGA
AAGCCGTTGCCTATGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACATGGAATTGTG
GTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATGGCAATTGCT
GATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACCCGACCATCG
AATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTGCTTGGTCAC
CCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAAAGCATATGC
AATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAATGCAAAGCGC
ATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCTGAAGATTTA
GAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATCATGCGCCTC
TCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTCTGGGTGGAG
TTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGACCTCACCTGG
TACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTGACAGTGGCC
TTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAAAAAGGGCGA
GTTAAGAAAGCCCACAAATCCAAGACCCATTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>530</residue_number>
    <molecular_weight>59940.495</molecular_weight>
    <theoretical_pi>7.895</theoretical_pi>
    <pfams>
      <pfam>
        <name>UDPGT</name>
        <pfam_id>PF00201</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;UDP-glucuronosyltransferase 1-9
MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLILRGHEVVVVMP
EVSWQLGRSLNCTVKTYSTSYTLEDLDREFKAFAHAQWKAQVRSIYSLLMGSYNDIFDLF
FSNCRSLFKDKKLVEYLKESSFDAVFLDPFDNCGLIVAKYFSLPSVVFARGILCHYLEEG
AQCPAPLSYVPRILLGFSDAMTFKERVRNHIMHLEEHLLCHRFFKNALEIASEILQTPVT
EYDLYSHTSIWLLRTDFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIV
VFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGH
PMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDL
ENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTW
YQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH</protein_sequence>
  </protein_properties>
  <genbank_protein_id>3025896</genbank_protein_id>
  <uniprot_id>O60656</uniprot_id>
  <uniprot_name>UD19_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AF056188</genbank_gene_id>
  <genecard_id>UGT1A9</genecard_id>
  <geneatlas_id>UGT1A9</geneatlas_id>
  <hgnc_id>HGNC:12541</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Wooster R, Sutherland L, Ebner T, Clarke D, Da Cruz e Silva O, Burchell B: Cloning and stable expression of a new member of the human liver phenol/bilirubin: UDP-glucuronosyltransferase cDNA family. Biochem J. 1991 Sep 1;278 ( Pt 2):465-9.</reference_text>
      <pubmed_id>1910331</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, Popescu NC: Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001 Jun;11(4):357-68.</reference_text>
      <pubmed_id>11434514</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
    <reference>
      <reference_text>Menard V, Girard H, Harvey M, Perusse L, Guillemette C: Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat. 2009 Apr;30(4):677-87.</reference_text>
      <pubmed_id>19204906</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Valproic acid glucuronide</name>
        <accession>HMDB00901</accession>
      </metabolite>
      <reference>
        <reference_text>Ethell BT, Anderson GD, Burchell B: The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 2003 May 1;65(9):1441-9.</reference_text>
        <pubmed_id>12732356</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicotine glucuronide</name>
        <accession>HMDB01272</accession>
      </metabolite>
      <reference>
        <reference_text>Kuehl GE, Murphy SE: N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2003 Nov;31(11):1361-8.</reference_text>
        <pubmed_id>14570768</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetaminophen glucuronide</name>
        <accession>HMDB10316</accession>
      </metabolite>
      <reference>
        <reference_text>Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI: Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther. 2001 Dec;299(3):998-1006.</reference_text>
        <pubmed_id>11714888</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethyl glucuronide</name>
        <accession>HMDB10325</accession>
      </metabolite>
      <reference>
        <reference_text>Foti RS, Fisher MB: Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucuronide in human liver microsomes and recombinant UGTs. Forensic Sci Int. 2005 Oct 29;153(2-3):109-16. Epub 2005 Jan 15.</reference_text>
        <pubmed_id>16139098</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketoprofen glucuronide</name>
        <accession>HMDB10334</accession>
      </metabolite>
      <reference>
        <reference_text>Kuehl GE, Lampe JW, Potter JD, Bigler J: Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35. Epub 2005 Apr 20.</reference_text>
        <pubmed_id>15843492</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Retinyl beta-glucuronide</name>
        <accession>HMDB10340</accession>
      </metabolite>
      <reference>
        <reference_text>Genchi G, Wang W, Barua A, Bidlack WR, Olson JA: Formation of beta-glucuronides and of beta-galacturonides of various retinoids catalyzed by induced and noninduced microsomal UDP-glucuronosyltransferases of rat liver. Biochim Biophys Acta. 1996 Mar 15;1289(2):284-90.</reference_text>
        <pubmed_id>8600986</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>1-(alpha-Methyl-4-(2-methylpropyl)benzeneacetate)-beta-D-Glucopyranuronic acid</name>
        <accession>HMDB10343</accession>
      </metabolite>
      <reference>
        <reference_text>Kuehl GE, Lampe JW, Potter JD, Bigler J: Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35. Epub 2005 Apr 20.</reference_text>
        <pubmed_id>15843492</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycotinine</name>
        <accession>HMDB01390</accession>
      </metabolite>
      <reference>
        <reference_text>Yamanaka H, Nakajima M, Katoh M, Kanoh A, Tamura O, Ishibashi H, Yokoi T: Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes. Drug Metab Dispos. 2005 Jan;33(1):23-30. Epub 2004 Oct 6.</reference_text>
        <pubmed_id>15470160</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B: Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. Epub 2010 Aug 13.</reference_text>
        <pubmed_id>20706860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Keating GM, Santoro A: Sorafenib: a review of its use in advanced hepatocellular carcinoma.  Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006.</reference_text>
        <pubmed_id>19228077</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mycophenolate mofetil</name>
        <accession>HMDB14826</accession>
      </metabolite>
      <reference>
        <reference_text>Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6.</reference_text>
        <pubmed_id>15470161</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurbiprofen</name>
        <accession>HMDB14850</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nateglinide</name>
        <accession>HMDB14869</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Irinotecan</name>
        <accession>HMDB14900</accession>
      </metabolite>
      <reference>
        <reference_text>Chabot GG: Clinical pharmacokinetics of irinotecan.  Clin Pharmacokinet. 1997 Oct;33(4):245-59.</reference_text>
        <pubmed_id>9342501</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxypropofol</name>
        <accession>HMDB14018</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxypropofol</name>
        <accession>HMDB14018</accession>
      </metabolite>
      <reference>
        <reference_text>Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):131-6.</reference_text>
        <pubmed_id>18816295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mycophenolic acid</name>
        <accession>HMDB15159</accession>
      </metabolite>
      <reference>
        <reference_text>Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. Epub 2010 Dec 1.</reference_text>
        <pubmed_id>21123165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mycophenolic acid</name>
        <accession>HMDB15159</accession>
      </metabolite>
      <reference>
        <reference_text>Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6.</reference_text>
        <pubmed_id>15470161</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Niflumic Acid</name>
        <accession>HMDB15573</accession>
      </metabolite>
      <reference>
        <reference_text>Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6.</reference_text>
        <pubmed_id>16278927</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
